Real World Experience with Tofacitinib in IBD at a Tertiary Center

BACKGROUND AND AIMS: Many inflammatory bowel disease (IBD) patients do not respond to medical therapy. Tofacitinib is a first in class, partially selective inhibitor of Janus kinase, recently approved for treating patients with ulcerative colitis (UC). We describe our experience with the use of tofa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Dig Dis Sci
Huvudupphovsmän: Weisshof, Roni, Golan, Maya A., Sossenheimer, Philip H., Jurdi, Katia El, Ollech, Jacob E., Pekow, Joel, Cohen, Russel D., Sakuraba, Atsushi, Dalal, Sushila, Rubin, David T.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2019
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935176/
https://ncbi.nlm.nih.gov/pubmed/30734234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-019-05492-y
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk